Ga naar de inhoud
  • Country
    • Finland
    • France
    • Germany
    • Greece
    • Italy
    • Ireland
    • Japan
    • Netherlands
    • Poland
    • Spain
    • United Kingdom
    • USA
  • VPAGs
    • AEVASI
    • AIVA
    • APACS
    • Association Takayasu France
    • ELEANA
    • France Vascularites
    • Kosapo
    • SHG Mainz
    • Suomen Vaskuliittiyhdistys ry
    • Vaskulitis e.V.
    • Vasculitis Foundation
    • Vasculitis Netherlands
    • Vasculitis Poland
    • Vasculitis UK
    • VIA
  • Hospitals
  • Institutions
  • Projects
    • Overview Projects
    • 2024 AAV Patient Summit
    • 2024 Barcelona Patient Conference
      • About Barcelona 2024
      • Videos Patient Conference Barcelona 2024
      • Videos Talkshows Barcelona 2024
    • 2023 AAV Summit Madrid
    • 2022 Dublin Patient Conference
      • About Dublin 2022
      • Videos Patient Conference Dublin 2022
      • Videos Talkshows Dublin 2022
    • FAIRVASC
    • Rare Revolution Magazine
    • SEE ME. HEAR ME.
    • VOICES
  • Diseases

    Introduction

    • Vasculitis Classification

    Large Vessel Vasculitis

    • GCA (Giant Cell Arteritis)
    • Takayasu

    Small Vessel Vasculitis

    AAV (ANCA Associated Vasculitis)

    • EGPA
    • GPA
    • MPA

    Immune Complex Vasculitis

    • Cryoglobulinemic Vasculitis
    • IgA vasculitis (Henoch Schönlein)
    • Anti GBM Vasculitis (Goodpasture)
    • Anti C1q vasculitis (hypocomplementic)

    Medium Vessel Vasculitis

    • PAN (Polyarteritis Nodosa)
    • Kawasaki Disease

    Variable Vessel Vasculitis

    • Behçet
    • Cogan Syndrome

    Single Organ Vascilitus

    • Cutaneous Leucoclastic Vasculitis
  • News
  • About Us
    • Contact us
    • Our Mission
    • A Registered Charity
  • ...

    NEWS

    What is happening in the world of Vasculitis ?

    tintrial
    • Peter Verhoeven
    • februari 19, 2021
    • 4:04 pm

    Results ADVOCATE study in NEJM

    Today February 18th 2021 the results of an important clinical study were published in the New England Journal of Medicine.


    The trial was conducted from March 15, 2017, until November 1, 2019 (last trial visit).


    In a phase 3 randomized trial (ADVOCATE) the avacopan product was compared with a tapering schedule of prednisone in patients with ANCA-associated vasculitis concurrently treated with immunosuppressive drugs.


    Patients were enrolled at 143 centers in an international, randomized, double-blind, double-dummy, controlled trial. The aim was to evaluate whether avacopan could replace a glucocorticoid-tapering regimen used in the treatment of ANCA-associated vasculitis

    Avacopan (30 mg twice daily) or matching placebo was given for 52 weeks, with 8 weeks of follow-up. Prednisone or a matched placebo was given on a tapering schedule for 20 weeks (60 mg per day tapered to discontinuation by week 21)


    The conclusion as published was:

    In this trial involving patients with ANCA-associated vasculitis, avacopan was noninferior but not superior to prednisone taper with respect to remission at week 26 and was superior to prednisone taper with respect to sustained remission at week 52. All the patients received cyclophosphamide or rituximab. The safety and clinical effects of avacopan beyond 52 weeks were not addressed in the trial.


    According to the authors “Longer trials are required to determine the durability and safety of avacopan in patients with ANCA-associated vasculitis,”.

    Source NEJM 18th Feb 2021

    NextPatient Conference DublinNext

    collaborate

    join us today 

    Do it Now

    About us

    • We encourage and support Vasculitis Patient Advocacy Groups (VPAGs) to collaborate and grow stronger.
    • If there is no existing VPAG in a particular country we can  help to create one.
    • We collaborate with any institution willing to help us in achieving these goals.

    Find

    VPAGs

    Hospitals

    Countries

    Projects

    Act

    Talk to us

    Join us

    Social Media
    Facebook-f Twitter Google-plus-g Youtube Linkedin-in